MedTrace Logo

A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer

NCT06760364 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2025-04-10

No results posted yet for this study

Summary

Evaluate the safety and efficacy of mesothelin-targeting UCAR-T cells in the treatment of mesothelin-positive advanced pancreatic cancer

Conditions

  • Advanced Pancreatic Cancers

Interventions

DRUG

CHT102

CHT 102 : MSLN UCAR-T.

Sponsors & Collaborators

  • Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd.

    collaborator INDUSTRY

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-25
Primary Completion
2027-12-24
Completion
2039-12-24

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06760364 on ClinicalTrials.gov